RxElite, Inc.

RxElite is a specialty pharmaceutical company that develops, manufactures, and markets generic prescription drug products in specialty generic markets. These markets include products in the areas of anesthesia, sterile liquid dose drugs (including respiratory inhalation drugs, ophthalmics, and injectable drugs), and transdermal patch products.

By utilizing ‘best in class’ manufacturing and research and development partners, RxElite has created a dynamic, integrated team with a deep knowledge of the generic prescription pharmaceutical market. RxElite has built a strong base in sterile liquid dose manufacturing and is continuing to add select oral solid dose manufacturing capabilities.

The RxElite management team brings together experience in customer relationship management, pharmaceutical manufacturing, generic pharmaceutical development, distribution, and finance.

Founded in December 2000, RxElite has built significant sales and distribution channels in the U.S. Market. RxElite has implemented an aggressive generic product development and launch plan that will considerably strengthen our product portfolio over the next five years, through internal ANDA registrations and growing our partnerships with major international generic manufacturers.

Positioned as a strong player in the generic pharmaceutical market, RxElite is committed to providing the highest quality products at the best prices, with 100% deliverability.

We are committed to provide the following benefits to our clients and their customers:

• Quality – RxElite products meet or exceed the industry’s highest quality standards ensuring long-term satisfied customers.
  
  
• Price – Utilizing the latest manufacturing technology and low cost distribution methods, RxElite is positioned to maintain price leadership.
  
  
• Deliverability – RxElite has maintained a 100% order fulfillment rate since inception and will continue to strive to meet this standard.

RxElite has implemented an aggressive generic product development and launch plan that will considerably strengthen our product portfolio over the next five years, through internal ANDA registrations and growing our partnerships with major international generic manufacturers.

RxElite’s end goal: To be the generic buyer’s ‘vendor of choice’ in each of our products.